Immunizations in the Nursery

  • Johanna M. Ascher BartlettEmail author


Immunizations are a critical feature of preventative care for term and preterm newborns. All infants, regardless of gestational age, should receive hepatitis B vaccine shortly after delivery. For preterm infants who remain in the neonatal intensive care unit, providers may be tasked with administering their 2-, 4-, 6-, or even 12-month vaccines. Ensuring that these immunizations are given promptly will prevent under-immunization at the time of nursery discharge. In addition, preterm infants may be eligible for one or both of influenza vaccination or palivizumab administration depending on risk factors and the time of year. The appropriate timing and indications for these immunizations for term and preterm infants are described in this chapter.


Hepatitis B Immunization Influenza Palivizumab Vaccine 


  1. 1.
    Zhao Z, Murphy TV. Which newborns missed the hepatitis B birth dose vaccination among U.S. children? Prev Med. 2013;57:613–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Meleth S, Dahlgren LS, Sankaran R, Sankaran K. Vaccination of infants discharged from a neonatal intensive care unit. CMAJ. 1995;153:415–9.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Navar-Boggan AM, Halsey NA, Escobar GJ, Golden WC, Klein NP. Underimmunization at discharge from the neonatal intensive care unit. J Perinatol. 2012;32:363–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Ko SC, Fan L, Smith EA, et al. Estimated annual perinatal hepatitis B virus infections in the United States, 2000-2009. J Pediatric Infect Dis Soc. 2016;5:114–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Stevens CE, Toy P, Kamili S, et al. Eradicating hepatitis B virus: the critical role of preventing perinatal transmission. Biologicals. 2017;50:3–19.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328–36.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW. Update: shortened interval for postvaccination serologic testing of infants born to hepatitis B-infected mothers. MMWR Morb Mortal Wkly Rep. 2015;64:1118–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Ben Jmaa W, Hernandez AI, Sutherland MR, et al. Cardiorespiratory events and inflammatory response after primary immunization in preterm infants <32 weeks gestational age: a randomized controlled study. Pediatr Infect Dis J. 2017;36:988–94.CrossRefPubMedGoogle Scholar
  9. 9.
    Montague EC, Hilinski JA, Williams HO, et al. Respiratory decompensation and immunization of preterm infants. Pediatrics. 2016;137:e20154225.CrossRefPubMedGoogle Scholar
  10. 10.
    DeMeo SD, Raman SR, Hornik CP, et al. Adverse events after routine immunization of extremely-low-birth-weight infants. JAMA Pediatr. 2015;169:740–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Maltezou HC, Ftika L, Theodoridou M. Nosocomial pertussis in neonatal units. J Hosp Infect. 2013;85:243–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Klein NP, Massolo ML, Greene J, et al. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pediatrics. 2008;121:463–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Yasmin S, Sunenshine R, Bisgard KM, et al. Healthcare-associated pertussis outbreak in Arizona: challenges and economic impact, 2011. J Pediatric Infect Dis Soc. 2014;3:81–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Robinson MJ, Heal C, Gardener E, Powell P, Sims DG. Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease. Pediatrics. 2004;113:733–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsuda K, Iwasaki S, Horiguchi H, et al. Immune response to Haemophilus influenzae type b conjugate vaccine in preterm infants. Pediatr Int. 2012;54:64–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Wysocki J, Center KJ, Brzostek J, et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. Vaccine. 2017;35:1926–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Sharma R, Hudak ML, Premachandra BR, et al. Clinical manifestations of rotavirus infection in the neonatal intensive care unit. Pediatr Infect Dis J. 2002;21:1099–105.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rotbart HA, Nelson WL, Glode MP, et al. Neonatal rotavirus-associated necrotizing enterocolitis: case control study and prospective surveillance during an outbreak. J Pediatr. 1988;112:87–93.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jaques S, Bhojnagarwala B, Kennea N, Duffy D. Slow uptake of rotavirus vaccination in UK neonatal units. Arch Dis Child Fetal Neonatal Ed. 2014;99:F252.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Stumpf KA, Thompson T, Sanchez PJ. Rotavirus vaccination of very low birth weight infants at discharge from the NICU. Pediatrics. 2013;132:e662–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Newman RD, Grupp-Phelan J, Shay DK, Davis RL. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics. 1999;103:E3.CrossRefPubMedGoogle Scholar
  22. 22.
    Anagnostropoulos D, Valioulis J, Sfougaris D, Maliaropoulos N, Spyridakis J. Morbidity and mortality of short bowel syndrome in infancy and childhood. Eur J Pediatr Surg. 1991;1:273–6.CrossRefGoogle Scholar
  23. 23.
    Thrall S, Doll MK, Nhan C, et al. Evaluation of pentavalent rotavirus vaccination in neonatal intensive care units. Vaccine. 2015;33:5095–102.CrossRefPubMedGoogle Scholar
  24. 24.
    Monk HM, Motsney AJ, Wade KC. Safety of rotavirus vaccine in the NICU. Pediatrics. 2014;133:e1555–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Fang AY, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J Paediatr Child Health. 2012;48(6):512.CrossRefPubMedGoogle Scholar
  26. 26.
    Javid PJ, Sanchez SE, Jacob S, et al. The safety and immunogenicity of rotavirus vaccination in infants with intestinal failure. J Pediatric Infect Dis Soc. 2014;3:57–65.CrossRefPubMedGoogle Scholar
  27. 27.
    Hiramatsu H, Suzuki R, Nagatani A, et al. Rotavirus vaccination can be performed without viral dissemination in the neonatal intensive care unit. J Infect Dis. 2018;217:589–96.CrossRefPubMedGoogle Scholar
  28. 28.
    Rivera L, Pena LM, Stainier I, et al. Horizontal transmission of a human rotavirus vaccine strain – a randomized, placebo-controlled study in twins. Vaccine. 2011;29:9508–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics. 2010;125:e438–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations from the committee on immunization practices – United States, 2017-18 influenza season. MMWR Recomm Rep. 2017;66:1–20.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tinnion RJ, Berrington JE. Flu vaccination for ex-preterms and infants under 6 months – are we getting it right? Arch Dis Child. 2010;95:400–1.CrossRefPubMedGoogle Scholar
  32. 32.
    Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371:918–31.CrossRefPubMedGoogle Scholar
  33. 33.
    McLellan JS, Ray WC, Peeples ME. Structure and function of RSV surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83–104.PubMedPubMedCentralGoogle Scholar
  34. 34.
    The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7.CrossRefGoogle Scholar
  35. 35.
    Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–20.CrossRefGoogle Scholar
  37. 37.
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Clin Ther. 2004;26:2130–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Texas Health Science Center San AntonioSan AntonioUSA

Personalised recommendations